Ítem
Acceso Abierto

Plasmodium falciparum pre-erythrocytic stage vaccine development

dc.creatorMolina-Franky, Jessicaspa
dc.creatorCuy-Chaparro, Lauraspa
dc.creatorCamargo, Annyspa
dc.creatorReyes, Césarspa
dc.creatorGómez, Marcelaspa
dc.creatorSalamanca, David Ricardospa
dc.creatorPatarroyo, Manuel A.
dc.creatorPatarroyo, Manuel Elkinspa
dc.date.accessioned2020-05-25T23:56:53Z
dc.date.available2020-05-25T23:56:53Z
dc.date.created2020spa
dc.description.abstractWorldwide strategies between 2010 and 2017 aimed at controlling malarial parasites (mainly Plasmodium falciparum) led to a reduction of just 18% regarding disease incidence rates. Many biologically-derived anti-malarial vaccine candidates have been developed to date; this has involved using many experimental animals, an immense amount of work and the investment of millions of dollars. This review provides an overview of the current state and the main results of clinical trials for sporozoite-targeting vaccines (i.e. the parasite stage infecting the liver) carried out by research groups in areas having variable malaria transmission rates. However, none has led to promising results regarding the effective control of the disease, thereby making it necessary to complement such efforts at finding/introducing new vaccine candidates by adopting a multi-epitope, multi-stage approach, based on minimal subunits of the main sporozoite proteins involved in the invasion of the liver. © 2020 The Author(s).eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1186/s12936-020-3141-z
dc.identifier.issn14752875
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22549
dc.language.isoengspa
dc.publisherBioMed Central Ltd.spa
dc.relation.citationIssueNo. 1
dc.relation.citationTitleMalaria Journal
dc.relation.citationVolumeVol. 19
dc.relation.ispartofMalaria Journal, ISSN:14752875, Vol.19, No.1 (2020)spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85078940008&doi=10.1186%2fs12936-020-3141-z&partnerID=40&md5=d3f9d750683e5fb5ce0994a301a33edcspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAtovaquone plus proguanilspa
dc.subject.keywordAzithromycinspa
dc.subject.keywordChimpanzee adenovirus 63 modified vaccinia virusspa
dc.subject.keywordChloroquinespa
dc.subject.keywordCsvac vaccinespa
dc.subject.keywordGenetically attenuated sporozoite vaccinespa
dc.subject.keywordLive vaccinespa
dc.subject.keywordMalaria vaccinespa
dc.subject.keywordMefloquinespa
dc.subject.keywordMva metrap vaccinespa
dc.subject.keywordPyrimethaminespa
dc.subject.keywordR21 vaccinespa
dc.subject.keywordRadiation attenuated sporozoitespa
dc.subject.keywordRecombinant protein vaccinespa
dc.subject.keywordRecombinant viral vector vaccinespa
dc.subject.keywordRtseng
dc.subject.keywordUnclassified drugspa
dc.subject.keywordVirus vectorspa
dc.subject.keywordDrug safetyspa
dc.subject.keywordHepatitisspa
dc.subject.keywordHumanspa
dc.subject.keywordMalariaspa
dc.subject.keywordMalaria controlspa
dc.subject.keywordNonhumanspa
dc.subject.keywordPlasmodium (life cycle stage)spa
dc.subject.keywordPlasmodium falciparumspa
dc.subject.keywordReviewspa
dc.subject.keywordSporozoitespa
dc.subject.keywordVaccination coveragespa
dc.subject.keywordVaccine immunogenicityspa
dc.subject.keywordVaccine productionspa
dc.subject.keywordClinical trialspa
dc.subject.keywordImmune responsespa
dc.subject.keywordMalariaspa
dc.subject.keywordSporozoitespa
dc.subject.keywordVaccinespa
dc.subject.keywordVaccine efficacyspa
dc.titlePlasmodium falciparum pre-erythrocytic stage vaccine developmentspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Cargando...
Miniatura
Nombre:
s12936-020-3141-z.pdf
Tamaño:
2.8 MB
Formato:
Adobe Portable Document Format
Descripción:
Colecciones